Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth

• Autor(a) principal: Li, Hai
• Data de Publicação: 2016
• Outros Autores: Kuwajima,Takaaki, Oakley, Derek, Nikulina, Elena, Hou, Jianwei, Yang, Wan Seok, Lowry, Emily Rhodes, Lamas, Nuno Jorge, Amoroso, Mackenzie Weygandt, Croft, Gist F., et. al.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/1822/50999
• topic: Ciências Médicas::Medicina Básica; Science & Technology

Suboptimal axonal regeneration contributes to the consequences of nervous system trauma and neurodegenerative disease, but the intrinsic mechanisms that regulate axon growth remain unclear. We screened 50,400 small molecules for their ability to promote axon outgrowth on inhibitory substrata. The most potent hits were the statins, which stimulated growth of all mouse- and human-patient-derived neurons tested, both in vitro and in vivo, as did combined inhibition of the protein prenylation enzymes farnesyltransferase (PFT) and geranylgeranyl transferase I (PGGT-1). Compensatory sprouting of motor axons may delay clinical onset of amyotrophic lateral sclerosis (ALS). Accordingly, elevated levels of PGGT1B, which would be predicted to reduce sprouting, were found in motor neurons of early-versus late-onset ALS patients postmortem. The mevalonate-prenylation pathway therefore constitutes an endogenous brake on axonal growth, and its inhibition provides a potential therapeutic approach to accelerate neuronal regeneration in humans.